Euroapi Past Earnings Performance
Past criteria checks 0/6
Euroapi's earnings have been declining at an average annual rate of -72.5%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually. Revenues have been growing at an average rate of 3.7% per year.
Key information
-72.5%
Earnings growth rate
-72.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 3.7% |
| Return on equity | -20.4% |
| Net Margin | -18.6% |
| Next Earnings Update | 31 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Euroapi makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,019 | -190 | 134 | 30 |
| 30 Sep 23 | 1,006 | -79 | 135 | 27 |
| 30 Jun 23 | 994 | 31 | 137 | 24 |
| 31 Mar 23 | 987 | 8 | 133 | 23 |
| 31 Dec 22 | 981 | -15 | 129 | 22 |
| 30 Sep 22 | 962 | -3 | 120 | 20 |
| 30 Jun 22 | 944 | 10 | 110 | 18 |
| 31 Mar 22 | 918 | 1 | 100 | 18 |
| 31 Dec 21 | 893 | -8 | 90 | 17 |
| 31 Dec 20 | 945 | -6 | 71 | 20 |
| 31 Dec 19 | 916 | 3 | 66 | 16 |
Quality Earnings: EAPIP is currently unprofitable.
Growing Profit Margin: EAPIP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EAPIP is unprofitable, and losses have increased over the past 5 years at a rate of 72.5% per year.
Accelerating Growth: Unable to compare EAPIP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EAPIP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: EAPIP has a negative Return on Equity (-20.45%), as it is currently unprofitable.